{"content":"<li class=\"n-box-item date-title\" data-end=\"1504151999\" data-start=\"1504065600\" data-txt=\"Monday, December 23, 2019\">Wednesday, August 30, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3292823\" data-ts=\"1504133455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292823-comcast-sues-vermont-puc-over-franchise-conditions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comcast sues Vermont PUC over franchise conditions</a></h4><ul>   <li>Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+1.6%</font>) has <a href=\"http://www.fiercecable.com/cable/comcast-sues-vermont-puc-over-franchise-conditions\" target=\"_blank\">sued Vermont's Public Utilities Commission</a>, a month after the agency denied a request to lighten the requirements in its franchise agreement.</li>    <li>The company requested the removal of requirements tied to network expansion and to public educational and government channels, but the PUC rebuffed the request.</li>    <li>Comcast says integrating the PEG channels into its interactive guide (not just the scrolling program grid) could cost $4M, and that customers don't want to pay for that.</li>    <li>It's also objecting to a requirement to build out 550 miles of new cable; Comcast says the conditions \"contravene federal and state law, amount to undue speaker-based burdens on Comcast&rsquo;s protected speech under the First Amendment.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292823\" data-linked=\"Comcast sues Vermont PUC over franchise conditions\" data-tweet=\"$CMCSA - Comcast sues Vermont PUC over franchise conditions https://seekingalpha.com/news/3292823-comcast-sues-vermont-puc-over-franchise-conditions?source=tweet\" data-url=\"https://seekingalpha.com/news/3292823-comcast-sues-vermont-puc-over-franchise-conditions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292820\" data-ts=\"1504130670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRP\" target=\"_blank\">CTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292820-ctrip-com-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ctrip.com beats by $0.02, beats on revenue</a></h4><ul><li>Ctrip.com (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRP' title='Ctrip.com International, Ltd.'>CTRP</a>): Q2 EPS of $0.22 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $953.13M (+43.9% Y/Y) <font color='green'>beats by $8.06M</font>.</li><li>Shares <font color='green'>+1.99%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16927995-ctrip-reports-unaudited-second-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292820\" data-linked=\"Ctrip.com beats by $0.02, beats on revenue\" data-tweet=\"$CTRP $TCOM - Ctrip.com beats by $0.02, beats on revenue https://seekingalpha.com/news/3292820-ctrip-com-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292820-ctrip-com-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292817\" data-ts=\"1504129412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292817-dryshipsminus-20-after-huge-q2-loss-sec-subpoena\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips -20% after huge Q2 loss, SEC subpoena</a></h4><ul>     <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) <font color='red'>-20.4%</font>&nbsp;AH after reporting a massive <a href=\"https://seekingalpha.com/news/3292773-dryships-reports-q2-results\" target=\"_blank\">Q2 loss</a> and revealing that it received a subpoena from the SEC for information related to its huge sale of stock between June 2016 and July 2017.</li>     <li>The dates include the period in which DRYS issued $700M in new shares, which wiped out the value of stock held by thousands of small investors.</li>     <li>DRYS <a href=\"https://www.wsj.com/articles/sec-issues-subpoena-to-dryships-1504128518\" target=\"_blank\">used the proceeds</a> from the offerings to purchase 17 vessels, including five controlled by companies associated with Chairman and CEO&nbsp;George Economou, who earns management fees on the company&rsquo;s fleet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292817\" data-linked=\"DryShips -20% after huge Q2 loss, SEC subpoena\" data-tweet=\"$DRYS - DryShips -20% after huge Q2 loss, SEC subpoena https://seekingalpha.com/news/3292817-dryshipsminus-20-after-huge-q2-loss-sec-subpoena?source=tweet\" data-url=\"https://seekingalpha.com/news/3292817-dryshipsminus-20-after-huge-q2-loss-sec-subpoena\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292816\" data-ts=\"1504129049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292816-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color='green'>+12.9%</font>. <a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a> <font color='green'>+2.8%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a> <font color='red'>-12.2%</font>. <a href='https://seekingalpha.com/symbol/NRP' title='Natural Resource Partners LP'>NRP</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='red'>-1.4%</font>. <a href='https://seekingalpha.com/symbol/ENLK' title='EnLink Midstream Partners, LP'>ENLK</a> <font color='red'>-1.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292816\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SCVL $KL $APEN - After Hours Gainers / Losers https://seekingalpha.com/news/3292816-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292816-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292814\" data-ts=\"1504127997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGI\" target=\"_blank\">ANGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292814-angies-list-sets-date-for-vote-on-iac-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Angie&#39;s List sets date for vote on IAC buyout</a></h4><ul>   <li>The S-4 statement for the acquisition of Angie's List (<a href=\"http://seekingalpha.com/symbol/ANGI\" target=\"_blank\">ANGI</a> <font color='red'>-2.4%</font>) by IAC/InterActiveCorp (<a href=\"http://seekingalpha.com/symbol/IAC\" target=\"_blank\">IAC</a> <font color='green'>+0.9%</font>) has been declared effective, and Angie's List has <a href=\"https://seekingalpha.com/pr/16927912-form-sminus-4-registration-statement-proposed-acquisition-angies-list-iac-interactivecorp\" target=\"_blank\">set the date for a special meeting</a>.</li>    <li>The close of business on Aug. 25 is the record date for a special shareholder meeting scheduled for Sept. 29 at 10 a.m. ET in Indianapolis.</li>    <li>Shareholders will take up the buyout as well as a nonbinding vote on executive compensation. IAC plans to combine Angie's List with its HomeAdvisor and create a new publicly traded company, ANGI Homeservices Inc.</li>    <li>Angie's List expects the deal to close in late Q3 or early Q4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292814\" data-linked=\"Angie&#39;s List sets date for vote on IAC buyout\" data-tweet=\"$ANGI $ANGI $IAC - Angie&#39;s List sets date for vote on IAC buyout https://seekingalpha.com/news/3292814-angies-list-sets-date-for-vote-on-iac-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3292814-angies-list-sets-date-for-vote-on-iac-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292807\" data-ts=\"1504126325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292807-fda-oks-tevas-austedo-for-tardive-dyskinesia-shares-ahead-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Teva&#39;s Austedo for tardive dyskinesia; shares ahead 1% after hours</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) <a href=\"https://seekingalpha.com/pr/16927807-teva-announces-fda-approval-austedo-deutetrabenazine-tablets-treatment-tardive-dyskinesia\" target=\"_blank\">announces </a>the FDA approval of AUSTEDO (deutetrabenazine) &nbsp;for the treatment of adults with tardive dyskinesia, a neurological disorder characterized by stiff jerky uncontrollable movements.</li><li>The FDA approved the drug in April for the treatment of chorea associated with Huntington's disease.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on average volume.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>5%</font>&nbsp;on Thursday in early trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292807\" data-linked=\"FDA OKs Teva&#39;s Austedo for tardive dyskinesia; shares ahead 1% after hours\" data-tweet=\"$TEVA - FDA OKs Teva&#39;s Austedo for tardive dyskinesia; shares ahead 1% after hours https://seekingalpha.com/news/3292807-fda-oks-tevas-austedo-for-tardive-dyskinesia-shares-ahead-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3292807-fda-oks-tevas-austedo-for-tardive-dyskinesia-shares-ahead-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292803\" data-ts=\"1504125887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292803-box-shares-slip-2-despite-q2-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Box shares slip 2% despite Q2 beats</a></h4><ul><li>Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) shares are&nbsp;<font color='red'>down 2%</font>&nbsp;aftermarket after reporting Q2 results with an EPS beat and narrow revenue beat with sales rising 28.5% on the prior year&rsquo;s quarter. Guidance for Q3 has revenue from $128M to $129M, which matches consensus at the low end, and loss per share from $0.14 to $0.13 matching at the high end. For the FY18, revenue straddles estimates at $128M to $129M and meets loss per share at the low end from $0.46 to $0.44.</li><li>Key metrics: Billings were up 31% to $139.5M. Customer count was up to over 76K businesses with new clients including Credit Karma, Cabot Energy, and Delta Global Services.</li><li>Key financials: Non-GAAP operating expenses totaled $129M, up 22% on the year. Net cash used in operating activities was $9.5M, up from the $4.9M last year. FCF was -$14.7M compared to -$8M. The company ended the quarter with $165M in cash and equivalents.</li><li><a href=\"https://seekingalpha.com/pr/16927834-box-reports-28-percent-revenue-growth-31-percent-billings-growth-fiscal-second-quarter-2018\" target=\"_blank\">Press release</a></li><li>Correction: updated Q2 to revenue beat instead of miss</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292769-box-beats-0_02-beats-revenue\" target=\"_blank\">Box beats by $0.02, beats on revenue</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292803\" data-linked=\"Box shares slip 2% despite Q2 beats\" data-tweet=\"$BOX - Box shares slip 2% despite Q2 beats https://seekingalpha.com/news/3292803-box-shares-slip-2-despite-q2-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3292803-box-shares-slip-2-despite-q2-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292791\" data-ts=\"1504124846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292791-vivus-settles-qsymia-patent-fight-dr-reddys-generic-version-allowed-june-1-2025-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus settles Qsymia patent fight with Dr. Reddy&#39;s, generic version allowed June 1, 2025; shares up 1% after hours</a></h4><ul><li>Vivus (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='Vivus, Inc.'>VVUS</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume on the heels of its Qysmia (phentermine and topiramate extended-release) patent infringement litigation <a href=\"https://seekingalpha.com/pr/16927833-vivus-announces-settlement-dr-reddys-laboratories-qsymia-r-patent-litigation\" target=\"_blank\">settlement </a>with Dr. Reddy's Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a>). The settlement agreement allows Dr. Reddy's to sell a generic version on June 1, 2025 or earlier under certain circumstances. If earlier, Vivus will receive a royalty on the sales of the generic.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292791\" data-linked=\"Vivus settles Qsymia patent fight with Dr. Reddy&#39;s, generic version allowed June 1, 2025; shares up 1% after hours\" data-tweet=\"$VVUS $VVUS $RDY - Vivus settles Qsymia patent fight with Dr. Reddy&#39;s, generic version allowed June 1, 2025; shares up 1% after hours https://seekingalpha.com/news/3292791-vivus-settles-qsymia-patent-fight-dr-reddys-generic-version-allowed-june-1-2025-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3292791-vivus-settles-qsymia-patent-fight-dr-reddys-generic-version-allowed-june-1-2025-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292785\" data-ts=\"1504124251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APEN\" target=\"_blank\">APEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292785-apollos-orbera365-ce-markd-shares-up-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apollo&#39;s ORBERA365 CE Mark&#39;d; shares up 3% after hours</a></h4><ul><li>Apollo Endosurgery (NASDAQ:<a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a>) <a href=\"https://seekingalpha.com/pr/16927821-apollo-endosurgery-announces-ce-mark-approval-orbera365-managed-weight-loss-system-expanding\" target=\"_blank\">announces </a>the CE Mark certification of its ORBERA365 Managed Weight Loss System. Commercial launch will commence in Q4.</li><li><a href=\"http://apolloendo.com/orbera/\" target=\"_blank\">ORBERA365 </a>is a non-surgical weight loss intervention to treat obesity. A deflated balloon is placed into the stomach via endoscope then filled with saline until it is the size of a grapefruit. After up to 12 months, the balloon is deflated and removed.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292785\" data-linked=\"Apollo&#39;s ORBERA365 CE Mark&#39;d; shares up 3% after hours\" data-tweet=\"$APEN - Apollo&#39;s ORBERA365 CE Mark&#39;d; shares up 3% after hours https://seekingalpha.com/news/3292785-apollos-orbera365-ce-markd-shares-up-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3292785-apollos-orbera365-ce-markd-shares-up-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292776\" data-ts=\"1504123876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292776-fidget-spinners-boost-for-five-below\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fidget spinners a boost for Five Below</a></h4><ul> <li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>) report comparable sales rose 9.3% in Q2 to sail past the 6.7% mark anticipated by analysts.</li> <li>\"We saw solid broad-based performance across our worlds, with notable contribution from the spinner trend,\" says CEO Joel Anderson.</li> <li>Net income improved 71% Y/Y to $16.8M for the quarter as margins expanded.</li> <li>Looking ahead, the retailer sees full year sales of $1.24B to $1.25B and EPS of $1.62 to $1.66 vs. $1.30 consensus.</li><li>FIVE&nbsp;<font color='green'>+3.21%</font>&nbsp;premarket to $50.85.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292776\" data-linked=\"Fidget spinners a boost for Five Below\" data-tweet=\"$FIVE - Fidget spinners a boost for Five Below https://seekingalpha.com/news/3292776-fidget-spinners-boost-for-five-below?source=tweet\" data-url=\"https://seekingalpha.com/news/3292776-fidget-spinners-boost-for-five-below\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292766\" data-ts=\"1504123349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292766-five-below-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below beats by $0.04, beats on revenue</a></h4><ul><li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>): Q2 EPS of $0.30 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $283.3M (+28.7% Y/Y) <font color='green'>beats by $6.66M</font>.</li><li>Shares <font color='green'>+6.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16927824-five-inc-announces-second-quarter-fiscal-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292766\" data-linked=\"Five Below beats by $0.04, beats on revenue\" data-tweet=\"$FIVE - Five Below beats by $0.04, beats on revenue https://seekingalpha.com/news/3292766-five-below-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292766-five-below-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292763\" data-ts=\"1504122566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292763-broadsoft-shares-up-10_9-on-sale-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BroadSoft shares up 10.9% on sale talks</a></h4><ul><li>        Software company BroadSoft (BSFT) is exploring strategic options including a possible sale, according to <a href=\"https://www.cnbc.com/2017/08/30/broadsoft-explores-potential-sale-sources-say-stock-jumps-10-percent.html\" target=\"_blank\">Reuters</a> sources.</li><li>                  BroadSoft&rsquo;s Q2 results included $88.8M in revenue, up 9% on the year, and a $3M net loss as the company struggles to compete with the likes of Cisco Systems and Ericsson.    </li><li>               Jefferies is assisting with the search for a potential seller or alternate strategy.&nbsp;</li><li>               BroadSoft shares are&nbsp;<font color='green'>up 10.86%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3292763\" data-linked=\"BroadSoft shares up 10.9% on sale talks\" data-tweet=\"$CSCO - BroadSoft shares up 10.9% on sale talks https://seekingalpha.com/news/3292763-broadsoft-shares-up-10_9-on-sale-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3292763-broadsoft-shares-up-10_9-on-sale-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292761\" data-ts=\"1504122036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292761-steelmakers-gain-on-talk-over-houston-scrap-supplies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelmakers gain on talk over Houston scrap supplies</a></h4><ul>     <li>U.S. Steel (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+3.6%</font>), AK Steel (<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+4.8%</font>), Nucor (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='green'>+1.3%</font>) and Steel Dynamics (<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='green'>+1%</font>) are higher amid speculation that flooded scrap yards in Houston could pinch steel supplies in the U.S. (NYSEARCA:<a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a>)</li>     <li>&ldquo;People are looking at the potential for extra steel demand from a bunch of scrap yards that are all flooded and out of commission, so tightening scrap in that region could help steel prices,&rdquo; Clarksons Platou analyst Lee McMillan tells Bloomberg, adding that &ldquo;historically, mini mills have looked to pass on higher scrap prices to customers.\"</li>     <li>McMillan estimates that ~200K automobiles and many appliances will be junked because of Harvey-related flooding, saying \"there&rsquo;s some incremental steel demand that will come of this - we just don&rsquo;t know how much.\"</li>     <li>KeyBanc's Philip Gibbs also sees U.S. ferrous metals including steel <a href=\"https://www.thestreet.com/story/14287460/1/steel-stocks-could-be-ready-to-benefit-as-harvey-drives-prices-higher.html\" target=\"_blank\">getting a boost in prices</a>, as Houston handles 30%-35% of U.S. steel imports, creating a \"relative tactical positive\" for steel companies.</li>     <li>Also: <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+4.5%</font>, <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='green'>+3%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+1.3%</font>.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292761\" data-linked=\"Steelmakers gain on talk over Houston scrap supplies\" data-tweet=\"$X $X $AKS - Steelmakers gain on talk over Houston scrap supplies https://seekingalpha.com/news/3292761-steelmakers-gain-on-talk-over-houston-scrap-supplies?source=tweet\" data-url=\"https://seekingalpha.com/news/3292761-steelmakers-gain-on-talk-over-houston-scrap-supplies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292758\" data-ts=\"1504121172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGI\" target=\"_blank\">SBGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292758-sinclair-broadcast-renews-five-fox-affiliation-deals-sharesplus-7_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinclair Broadcast renews five Fox affiliation deals; shares +7.2%</a></h4><ul>   <li>Sinclair Broadcast Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a>) has <font color='green'>jumped 7.2%</font> after setting an <a href=\"https://seekingalpha.com/pr/16927723-sinclair-announces-affiliation-agreement-renewals-fox-broadcasting-company-five-markets\" target=\"_blank\">affiliation renewal deal</a> with Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+0.4%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+0.5%</font>) for all five of its stations that had come to the end of their terms.</li>    <li>The company renewed Fox affiliations for WACH in Columbia, S.C.; KFOX in El Paso, Texas; KRXI in Reno, Nev.; WFXL in Albany, Ga.; and WSBT in South Bend, Ind.</li>    <li>The deal includes participation in vMVPD deals, Sinclair's Barry Faber says.</li>    <li>Other affiliations with Fox are up at the end of 2017 and in 2018.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292758\" data-linked=\"Sinclair Broadcast renews five Fox affiliation deals; shares +7.2%\" data-tweet=\"$SBGI $SBGI $FOX - Sinclair Broadcast renews five Fox affiliation deals; shares +7.2% https://seekingalpha.com/news/3292758-sinclair-broadcast-renews-five-fox-affiliation-deals-sharesplus-7_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3292758-sinclair-broadcast-renews-five-fox-affiliation-deals-sharesplus-7_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292755\" data-ts=\"1504120768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292755-amplify-snack-brands-pops-on-buyout-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amplify Snack Brands pops on buyout talk</a></h4><ul><li>Amplify Snack Brands (<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+3%</font>) shoots higher on a volume spike after sitting in negative territory.</li><li>Shares made their upward turn after <a href=\"http://www.dealreporter.com/info/\" target=\"_blank\">Dealreporter</a> tipped that the food company is pursuing a sale with the assistance of Jefferies.</li><li>Amplify trades down 18% for the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292755\" data-linked=\"Amplify Snack Brands pops on buyout talk\" data-tweet=\"$BETR $BETR-OLD - Amplify Snack Brands pops on buyout talk https://seekingalpha.com/news/3292755-amplify-snack-brands-pops-on-buyout-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3292755-amplify-snack-brands-pops-on-buyout-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292750\" data-ts=\"1504119361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292750-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ICAD' title='iCAD, Inc.'>ICAD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292750\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$MARK $FSNN $OLED - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3292750-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292750-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292744\" data-ts=\"1504116867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPC\" target=\"_blank\">MPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292744-marathon-petroleum-buckeye-partners-said-to-restart-texas-refineries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon Petroleum, Buckeye Partners said to restart Texas refineries</a></h4><ul>     <li>Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+2%</font>) reportedly is <a href=\"http://www.reuters.com/article/us-storm-harvey-energy-idUSKCN1BA1RD\" target=\"_blank\">restarting</a> its 459K bbl/day Galveston Bay refinery after it was shut by Tropical Storm Harvey.</li>     <li>Energy industry intelligence service Genscape says one of the refinery&rsquo;s two 225K bbl/day crude distillation units appears to have restarted based on an observation of activity levels at the unit.</li>     <li>Also, Buckeye Partners (<a href='https://seekingalpha.com/symbol/BPL' title='Buckeye Partners L.P.'>BPL</a> <font color='red'>-0.2%</font>) is said to have <a href=\"https://twitter.com/robert__gibbons/status/902936871021498368\" target=\"_blank\">re-started</a> its Corpus Christi terminal after shutting down due to Harvey.</li><li>Total (<a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a> <font color='red'>-0.6%</font>) expects water within its 225K bbl/day Port Arthur refinery to <a href=\"http://www.reuters.com/article/us-storm-harvey-total-portarthur-idUSKCN1BA2D1\" target=\"_blank\">recede by the weekend</a>, according to a separate report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292744\" data-linked=\"Marathon Petroleum, Buckeye Partners said to restart Texas refineries\" data-tweet=\"$MPC $MPC $BPL - Marathon Petroleum, Buckeye Partners said to restart Texas refineries https://seekingalpha.com/news/3292744-marathon-petroleum-buckeye-partners-said-to-restart-texas-refineries?source=tweet\" data-url=\"https://seekingalpha.com/news/3292744-marathon-petroleum-buckeye-partners-said-to-restart-texas-refineries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292743\" data-ts=\"1504116393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292743-netflixplus-3-after-bernstein-dismisses-disney-loss-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix +3% after Bernstein dismisses Disney loss impact</a></h4><ul>     <li>No Disney, no worries for Netflix says Bernstein in <a href=\"https://www.cnbc.com/2017/08/30/netflix-to-surge-20-percent-because-disneys-content-retraction-is-too-late-bernstein.html\" target=\"_blank\">backing</a> its Overweight rating on the streamer.</li>     <li>\"Almost all of Netflix's future growth will come from international &hellip; Investors who were already skeptical (or bullish) on int'l growth will remain so &ndash; but Disney's U.S. non-renewal should have no effect on that view,\" says analyst Todd Juenger.</li>     <li>\"In the U.S., recent news flow has, if anything, made us more bullish,\" he adds.</li>     <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is&nbsp;<font color='green'>up 3.10%</font>&nbsp;on the day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292743\" data-linked=\"Netflix +3% after Bernstein dismisses Disney loss impact\" data-tweet=\"$NFLX - Netflix +3% after Bernstein dismisses Disney loss impact https://seekingalpha.com/news/3292743-netflixplus-3-after-bernstein-dismisses-disney-loss-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3292743-netflixplus-3-after-bernstein-dismisses-disney-loss-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292742\" data-ts=\"1504116078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292742-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NRP' title='Natural Resource Partners LP'>NRP</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PGLC' title='Pershing Gold Corporation'>PGLC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TTI' title='Tetra Technologies Inc.'>TTI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292742\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CLMT $CGG-OLD $ZN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3292742-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292742-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292738\" data-ts=\"1504113759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292738-bluebird-bio-follows-through-up-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">bluebird bio follows through, up 12%</a></h4><ul><li>The market's enthusiasm for CAR-T developers after Gilead's announced takeover of Kite Pharma has not left bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+11.6%</font>) behind. Shares are up on 44% higher volume, following through on its Monday breakout from brief consolidation. The 52-week (and then some) high is $123.75, reached on June 22.</li><li>The company's lead CAR-T candidate is bb2121, in Stage 1 development for multiple myeloma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292738\" data-linked=\"bluebird bio follows through, up 12%\" data-tweet=\"$BLUE - bluebird bio follows through, up 12% https://seekingalpha.com/news/3292738-bluebird-bio-follows-through-up-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3292738-bluebird-bio-follows-through-up-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292737\" data-ts=\"1504113402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292737-francescas-earnings-setting-up-to-be-volatile-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s earnings setting up to be volatile event</a></h4><ul><li>Downside put options on Francesca's (<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='green'>+0.1%</font>) are the most active in the U.S., according to Bloomberg data.</li><li>The bets on Francesca's set up the company's earnings report on September 6 to be a high-volatility event. The retailer is expected to report Q2 revenue of $126M and EPS of $0.27.</li><li>Shares of Francesca's are already down 22% over the last month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292737\" data-linked=\"Francesca&#39;s earnings setting up to be volatile event\" data-tweet=\"$FRAN - Francesca&#39;s earnings setting up to be volatile event https://seekingalpha.com/news/3292737-francescas-earnings-setting-up-to-be-volatile-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3292737-francescas-earnings-setting-up-to-be-volatile-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292734\" data-ts=\"1504111963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRO\" target=\"_blank\">FRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292734-frontlineminus-7-after-q2-loss-and-seeing-weak-quarters-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontline -7% after Q2 loss and seeing weak quarters ahead</a></h4><ul>     <li>Frontline (<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a> <font color='red'>-7.6%</font>) sinks near 52-week lows after reporting a larger than expected <a href=\"https://seekingalpha.com/news/3292563-frontline-misses-0_07-beats-revenue\" target=\"_blank\">Q2 loss</a> and warning of difficult upcoming quarters.</li>     <li>FRO says the market for its tankers likely would <a href=\"http://www.nasdaq.com/article/tanker-firm-frontline-sees-weak-quarters-ahead-20170830-00089\" target=\"_blank\">remain weak for the next few quarters</a> due to overcapacity before beginning to improve in 2018, as the pace of deliveries of new vessels slows and older ships are retired from the global fleet.</li><li>Despite abandoning its effort to buy rival tanker firm DHT&nbsp;Holdings in June, CEO&nbsp;Robert Hvide Macleod says FRO will <a href=\"http://splash247.com/frontline-remains-hunt-attractive-opportunities-prolonged-weak-tanker-market/\" target=\"_blank\">continue to watch</a> for \"attractive opportunities to emerge as a result of the weak market and will remain opportunistic going forward.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3292734\" data-linked=\"Frontline -7% after Q2 loss and seeing weak quarters ahead\" data-tweet=\"$FRO - Frontline -7% after Q2 loss and seeing weak quarters ahead https://seekingalpha.com/news/3292734-frontlineminus-7-after-q2-loss-and-seeing-weak-quarters-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3292734-frontlineminus-7-after-q2-loss-and-seeing-weak-quarters-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292732\" data-ts=\"1504111502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292732-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/QRHC' title='Quest Resource Holding Corp.'>QRHC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color='red'>-82%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DY' title='Dycom Industries Inc.'>DY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292732\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$LINU-OLD $TCON $AVAV - Midday Gainers / Losers https://seekingalpha.com/news/3292732-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292732-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292728\" data-ts=\"1504110157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292728-intelsat-prepares-to-launch-fifth-next-gen-satellite\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat prepares to launch fifth next-gen satellite</a></h4><ul>   <li>Intelsat (<a href=\"http://seekingalpha.com/symbol/I\" target=\"_blank\">I</a> <font color='red'>-1.8%</font>) is readying the <a href=\"https://seekingalpha.com/pr/16927003-intelsat-37e-preparing-launch\" target=\"_blank\">launch of the fifth</a> of its next-generation satellites.</li>    <li>The company and Arianespace will launch Intelsat 37e, its latest high-throughput satellite, on Sept. 5 in French Guiana.</li>    <li>Its Boeing-made payload has full-beam interconnectivity in the C, Ku and Ka bands along with power-sharing and steerable beams in Ku and Ka bands.</li>    <li>The satellite will replace Intelsat 901, which will be repositioned.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292728\" data-linked=\"Intelsat prepares to launch fifth next-gen satellite\" data-tweet=\"$I - Intelsat prepares to launch fifth next-gen satellite https://seekingalpha.com/news/3292728-intelsat-prepares-to-launch-fifth-next-gen-satellite?source=tweet\" data-url=\"https://seekingalpha.com/news/3292728-intelsat-prepares-to-launch-fifth-next-gen-satellite\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292725\" data-ts=\"1504109738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292725-biogen-clears-consolidation-volume-light-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen clears consolidation but volume light, shares up 4%</a></h4><ul><li>In a post for chartists, Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+3.6%</font>) breaks out from a six-month base albeit on light volume.</li><li>Two days ago, it announced positive early-stage data on Alzheimer's candidate aducanumab. Last Friday, the European Commission approved its Humira biosimilar IMRALDI.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292104-biogens-alzheimers-candidate-aducanumab-shows-long-term-treatment-effect-extension-phase\" target=\"_blank\">Biogen's Alzheimer's candidate aducanumab shows long-term treatment effect in extension phase of early-stage study</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291765-biogens-humira-biosimilar-okd-europe\" target=\"_blank\">Biogen's Humira biosimilar OK'd in Europe</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292725\" data-linked=\"Biogen clears consolidation but volume light, shares up 4%\" data-tweet=\"$BIIB - Biogen clears consolidation but volume light, shares up 4% https://seekingalpha.com/news/3292725-biogen-clears-consolidation-volume-light-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3292725-biogen-clears-consolidation-volume-light-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292724\" data-ts=\"1504109656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIX\" target=\"_blank\">SIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292724-hilliard-lyons-sees-clear-skies-for-six-flags\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hilliard Lyons sees clear skies for Six Flags</a></h4><ul>     <li>Hilliard Lyons upgrades Six Flags Entertainment (<a href='https://seekingalpha.com/symbol/SIX' title='Six Flags Entertainment Corporation'>SIX</a> <font color='green'>+1.6%</font>) to a <a href=\"https://twitter.com/usratings/status/902911927940153345\" target=\"_blank\">Buy rating</a> on its view that investors are underestimating the long-term story.</li>     <li>We feel adverse weather has been the main reason for the share price weakness, despite having little to no correlation to future years,\" observes analyst Jeff Thomison.</li><li>Shares of Six Flags peaked in April at $65.19.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292724\" data-linked=\"Hilliard Lyons sees clear skies for Six Flags\" data-tweet=\"$SIX - Hilliard Lyons sees clear skies for Six Flags https://seekingalpha.com/news/3292724-hilliard-lyons-sees-clear-skies-for-six-flags?source=tweet\" data-url=\"https://seekingalpha.com/news/3292724-hilliard-lyons-sees-clear-skies-for-six-flags\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292721\" data-ts=\"1504108988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292721-investors-acknowledge-value-of-gileads-takeout-of-kite-pharma-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors acknowledge value of Gilead&#39;s takeout of Kite Pharma, shares up 6%</a></h4><ul><li>In a bit of a delayed response, buying has picked up in Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+5.5%</font>) two days after it announced that it will acquire Kite Pharma (<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+0.1%</font>) for $180/share ($11.9B). Volume is 70% above normal.</li><li>Gilead shares rose a modest 1% the day of the announcement and 1% the day after.</li><li>The announcement by Novartis that it has priced just-approved CAR-T Kymriah at $475K has certainly contributed to the bullishness since it bodes well for Kite's CAR-T axicabtagene ciloleucel.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11_9b-cash-kite-16-percent-premarket\" target=\"_blank\">Gilead takes out Kite Pharma for $11.9B in cash; Kite up 16% premarket</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292721\" data-linked=\"Investors acknowledge value of Gilead&#39;s takeout of Kite Pharma, shares up 6%\" data-tweet=\"$GILD $GILD $KITE - Investors acknowledge value of Gilead&#39;s takeout of Kite Pharma, shares up 6% https://seekingalpha.com/news/3292721-investors-acknowledge-value-of-gileads-takeout-of-kite-pharma-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3292721-investors-acknowledge-value-of-gileads-takeout-of-kite-pharma-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292720\" data-ts=\"1504108826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292720-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SUMR' title='Summer Infant, Inc.'>SUMR</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WILC' title='G. Willi-Food International, Ltd.'>WILC</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292720\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NBEV $REED $SGOC - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3292720-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292720-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292710\" data-ts=\"1504106936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSN\" target=\"_blank\">ALSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292710-piper-jaffray-warns-of-ev-impact-on-allison-transmission\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray warns of EV impact on Allison Transmission</a></h4><ul>     <li>Allison Transmission (<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='red'>-4%</font>) trades lower after Piper Jaffray lowers its price target on the Underweight-rated stock to <a href=\"https://twitter.com/RatingsNetwork/status/902850510776147968\" target=\"_blank\">$25</a>.</li>     <li>\"Electrification represents a secular threat, with near/medium term disruption in bus and refuse markets likely to eventually spread to all of ALSN&rsquo;s targeted segments,\" warns analyst Alexander Potter.</li><li>Shares of Allison Transmission are down 12% over the last 90 days.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292710\" data-linked=\"Piper Jaffray warns of EV impact on Allison Transmission\" data-tweet=\"$ALSN - Piper Jaffray warns of EV impact on Allison Transmission https://seekingalpha.com/news/3292710-piper-jaffray-warns-of-ev-impact-on-allison-transmission?source=tweet\" data-url=\"https://seekingalpha.com/news/3292710-piper-jaffray-warns-of-ev-impact-on-allison-transmission\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292707\" data-ts=\"1504106311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KHC\" target=\"_blank\">KHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292707-buffett-doesnt-see-kraft-mondelez-mega-food-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffett doesn&#39;t see Kraft-Mondelez mega food deal</a></h4><ul>     <li>CNBC asked Warren Buffett if he expected Kraft Heinz (<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a> <font color='green'>+0.5%</font>) to make a run at acquiring Mondelez International (<a href='https://seekingalpha.com/symbol/MDLZ' title='Mondelēz International, Inc.'>MDLZ</a> <font color='red'>-0.3%</font>).</li>     <li>\"I think the answer is no on that,\" responded Buffett.</li><li>Kraft and Mondelez have been linked in M&amp;A speculation since the Kraft-Heinz merger.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292707\" data-linked=\"Buffett doesn&#39;t see Kraft-Mondelez mega food deal\" data-tweet=\"$KHC $KHC $MDLZ - Buffett doesn&#39;t see Kraft-Mondelez mega food deal https://seekingalpha.com/news/3292707-buffett-doesnt-see-kraft-mondelez-mega-food-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3292707-buffett-doesnt-see-kraft-mondelez-mega-food-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292683\" data-ts=\"1504105956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292683-healthcare-top-5-gainers-losers-of-11-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:10 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color='red'>-80%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292683\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:10 am\" data-tweet=\"$IMGN $MZOR $CRBP - Healthcare - Top 5 Gainers / Losers as of 11:10 am https://seekingalpha.com/news/3292683-healthcare-top-5-gainers-losers-of-11-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3292683-healthcare-top-5-gainers-losers-of-11-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292700\" data-ts=\"1504104990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292700-fda-oks-novartis-car-t-for-all\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Novartis&#39; CAR-T for ALL</a></h4><ul><li>As expected, the FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm\" target=\"_blank\">approves</a> Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-0.9%</font>) Kymriah (tisagenlecleucel), a CAR-T immunotherapy for treatment-resistant B-cell acute lymphoblastic leukemia &#40;ALL&#41;, the first CAR-T approved in the U.S. for any indication.</li><li>The company <a href=\"https://globenewswire.com/news-release/2017/08/30/1104337/0/en/Novartis-receives-first-ever-FDA-approval-for-a-CAR-T-cell-therapy-Kymriah-TM-CTL019-for-children-and-young-adults-with-B-cell-ALL-that-is-refractory-or-has-relapsed-at-least-twice.html\" target=\"_blank\">says </a>it plans to file marketing applications in the U.S. and Europe later this year for adult patients with relapsed/refractory diffuse large B-cell lymphoma.</li><li>The FDA also approved the use of Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) <a href=\"https://www.actemra.com/?cid=act_PS_MIUARAPS0123_1&amp;c=MIUARAPS0123&amp;mkwid=s78Bt2nML_dc_pcrid_197845115484_pkw_actemra_pmt_e&amp;utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=Branded+%5BE%5D+%7C+Actemra+%7C+Patient+%7C+Branded+%7C+Actemra.com+%7C+RA+%7C+act_PS_00001401&amp;utm_term=actemra&amp;gclid=EAIaIQobChMI-MuB_pv_1QIVg5R-Ch2i0gCLEAAYASAAEgI6JPD_BwE\" target=\"_blank\">Actemra </a>(tocilizumab) to treat CAR-T-induced severe or life-threatening cytokine release syndrome &#40;CRS&#41;, a common adverse event with the therapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278282-fda-ad-com-unanimously-backs-novartis-car-t-shares-2-percent\" target=\"_blank\">FDA Ad Com unanimously backs Novartis' CAR-T for ALL; shares up 2%</a> (July 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292700\" data-linked=\"FDA OKs Novartis&#39; CAR-T for ALL\" data-tweet=\"$NVS $NVS $RHHBY - FDA OKs Novartis&#39; CAR-T for ALL https://seekingalpha.com/news/3292700-fda-oks-novartis-car-t-for-all?source=tweet\" data-url=\"https://seekingalpha.com/news/3292700-fda-oks-novartis-car-t-for-all\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292698\" data-ts=\"1504104459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAL\" target=\"_blank\">CAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292698-caleres-soars-after-strong-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caleres soars after strong Q2</a></h4><ul><li>Caleres (<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='green'>+9.9%</font>) trades higher after blowing past <a href=\"https://seekingalpha.com/pr/16926626-caleres-reports-second-quarter-2017-results\" target=\"_blank\">Q2</a> estimates.</li><li>The retailer recorded a 2.8% gain in comparable sales at Famous Footwear and saw gross margin arrive at 42.5% of sales vs. 41.9% consensus estimate.</li><li>Susquehanna sticks with a Positive rating on Caleres after taking in the annual guidance, noting that management was probably conservative with the full extent of Hurricane Harvey's impact on August sales not yet known.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292492-caleres-beats-0_04-beats-revenue\" target=\"_blank\">Caleres beats by $0.04, beats on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292698\" data-linked=\"Caleres soars after strong Q2\" data-tweet=\"$CAL - Caleres soars after strong Q2 https://seekingalpha.com/news/3292698-caleres-soars-after-strong-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3292698-caleres-soars-after-strong-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292696\" data-ts=\"1504103883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292696-qualcomm-and-himax-announce-3d-sensor-collab-qcom-joins-iot-alliance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm and Himax announce 3D sensor collab; QCOM joins IoT alliance</a></h4><ul><li>        Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) and Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>)&nbsp;<a href=\"https://www.qualcomm.com/news/releases/2017/08/30/qualcomm-and-himax-technologies-jointly-announce-high-resolution-3d-depth\" target=\"_blank\">announce</a> a collaboration to develop and commercialize high-res, low power active 3D depth sensing camera systems.</li><li>               The systems will enable computer vision capabilities including face authentication and scene perception across a range of industries including automotive, virtual reality, and IoT.&nbsp;</li><li>               The collaboration combines Qualcomm&rsquo;s Spectra tech and computer vision architecture with Himax&rsquo;s wafer optics, sensor, and driver technologies.&nbsp;</li><li>               In related news, Qualcomm <a href=\"https://www.qualcomm.com/news/releases/2017/08/30/qualcomm-joins-iot-cybersecurity-alliance\" target=\"_blank\">joins</a> the IoT Cybersecurity Alliance that also includes Palo Alto Networks, IBM, and Symantec.&nbsp;</li><li>               Qualcomm shares are&nbsp;<font color='green'>up 0.40%</font>.&nbsp;</li><li>               Himax Technologies shares are&nbsp;<font color='green'>up 2.9%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3292696\" data-linked=\"Qualcomm and Himax announce 3D sensor collab; QCOM joins IoT alliance\" data-tweet=\"$QCOM $QCOM $HIMX - Qualcomm and Himax announce 3D sensor collab; QCOM joins IoT alliance https://seekingalpha.com/news/3292696-qualcomm-and-himax-announce-3d-sensor-collab-qcom-joins-iot-alliance?source=tweet\" data-url=\"https://seekingalpha.com/news/3292696-qualcomm-and-himax-announce-3d-sensor-collab-qcom-joins-iot-alliance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292695\" data-ts=\"1504103857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKA\" target=\"_blank\">ROKA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292695-roka-files-preliminary-proxy-for-asset-sale-to-ieh-and-liquidation-of-company-shares-down-36\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roka files preliminary proxy for asset sale to IEH and liquidation of company; shares down 36%</a></h4><ul><li>Thinly traded nano cap Roka Bioscience (<a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-36.4%</font>) slumps on an 8x surge in volume in early trading. Yesterday evening, it<a href=\"https://www.sec.gov/Archives/edgar/data/1472343/000147234317000057/preliminaryapaproxy.htm\" target=\"_blank\"> filed its preliminary proxy</a> statement for the special shareholders meeting during which it will seek approval for the previously announced $17.5M asset sale to Institute for Environmental Health &#40;IEH&#41; and liquidation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290157-roka-bio-proceeds-liquidation-agrees-sell-assets-17_5m\" target=\"_blank\">Roka Bio proceeds with liquidation, agrees to sell all assets for $17.5M</a> (Aug. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292695\" data-linked=\"Roka files preliminary proxy for asset sale to IEH and liquidation of company; shares down 36%\" data-tweet=\"$ROKA - Roka files preliminary proxy for asset sale to IEH and liquidation of company; shares down 36% https://seekingalpha.com/news/3292695-roka-files-preliminary-proxy-for-asset-sale-to-ieh-and-liquidation-of-company-shares-down-36?source=tweet\" data-url=\"https://seekingalpha.com/news/3292695-roka-files-preliminary-proxy-for-asset-sale-to-ieh-and-liquidation-of-company-shares-down-36\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292692\" data-ts=\"1504103482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292692-eia-petroleum-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Petroleum Inventories</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-5.4M</strong> barrels vs. -1.9M consensus, -3.3M last week.</li><li>Gasoline <b>Unchanged</b>&nbsp;vs. -0.9M consensus, -1.2M last week.</li><li>Distillates&nbsp;<strong>+0.7M</strong> barrels&nbsp;vs. -0.8M consensus, +0.0M last week.</li><li>Futures&nbsp;<font color='red'>-0.69%</font>&nbsp;to $46.12.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292692\" data-linked=\"EIA Petroleum Inventories\" data-tweet=\"$USO $OIL $UCO - EIA Petroleum Inventories https://seekingalpha.com/news/3292692-eia-petroleum-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3292692-eia-petroleum-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292686\" data-ts=\"1504101869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292686-volatile-trading-on-sprouts-farmers-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatile trading on Sprouts Farmers Market</a></h4><ul> <li>Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>) is <font color='green'>up 1.86%</font> on heavy volume with some M&amp;A chatter floating around trading desks.</li> <li>Yesterday, call options activity was elevated on Sprouts. Bloomberg reports total call volume was 7X the 20-day average.</li><li>Shares of Sprouts are still down 18% since Amazon fired off notice last week of lower prices at Whole Foods.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292686\" data-linked=\"Volatile trading on Sprouts Farmers Market\" data-tweet=\"$SFM - Volatile trading on Sprouts Farmers Market https://seekingalpha.com/news/3292686-volatile-trading-on-sprouts-farmers-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3292686-volatile-trading-on-sprouts-farmers-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292679\" data-ts=\"1504101030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292679-eros-micromax-offering-content-filled-tablet-to-india\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros, Micromax offering content-filled tablet to India</a></h4><ul>   <li>Eros Now (<a href=\"http://seekingalpha.com/symbol/EROS\" target=\"_blank\">EROS</a> <font color='green'>+1.6%</font>), the streaming service of Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>), and Micromax Informatics are coming together on a <a href=\"https://seekingalpha.com/pr/16927143-micromax-partners-eros-now-launch-new-content-rich-tablet-indian-market\" target=\"_blank\">content-filled tablet</a> for the Indian market.</li>    <li>The tablet, Canvas Plex, will offer users a year's premium subscription and feature an 8-inch HD screen along with 3 GB of RAM, 32 GB of ROM and DTS sound.</li>    <li>It's launching Sept. 1 at a price of 12,999 rupees (about $203).</li>    <li>The two companies will also team up to promote upcoming Bollywood film <i>Shubh Mangal Saavdhan,</i> with some consumers winning VIP access to the film's stars.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292679\" data-linked=\"Eros, Micromax offering content-filled tablet to India\" data-tweet=\"$EROS - Eros, Micromax offering content-filled tablet to India https://seekingalpha.com/news/3292679-eros-micromax-offering-content-filled-tablet-to-india?source=tweet\" data-url=\"https://seekingalpha.com/news/3292679-eros-micromax-offering-content-filled-tablet-to-india\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292665\" data-ts=\"1504099514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEON\" target=\"_blank\">VEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292665-veonplus-2_4-on-940m-sale-of-pakistan-towers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veon +2.4% on $940M sale of Pakistan towers</a></h4><ul>   <li>Veon (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd. ADS'>VEON</a>) is <font color='green'>up 2.4%</font> premarket after it and Global Telecom Holding reached a deal for their Pakistan unit Jazz to <a href=\"https://seekingalpha.com/pr/16926795-veon-gth-sell-pakistan-tower-business-usd-940-million\" target=\"_blank\">sell its tower business, Deodar, for about $940M</a>.</li>    <li>The deal was <a href=\"https://seekingalpha.com/news/3292386-axiata-nears-1b-deal-veons-pakistan-mobile-towers\" target=\"_blank\">reported to be getting closer</a> yesterday.</li>    <li>The buyer, Tanzanite Tower Limited, is owned by Edotco Group (Axiata) and Dawood Hercules. It gets about 13,000 towers in the deal.</li>    <li>The enterprise value comes to a high single-digit multiple of combined annual EBITDA, a significant premium, Veon says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292665\" data-linked=\"Veon +2.4% on $940M sale of Pakistan towers\" data-tweet=\"$VEON - Veon +2.4% on $940M sale of Pakistan towers https://seekingalpha.com/news/3292665-veonplus-2_4-on-940m-sale-of-pakistan-towers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292665-veonplus-2_4-on-940m-sale-of-pakistan-towers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292664\" data-ts=\"1504099297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DY\" target=\"_blank\">DY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292664-dycomminus-12-following-revenue-miss-weakened-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dycom -12% following revenue miss, weakened guidance</a></h4><ul>     <li>Dycom Industries (NYSE:<a href='https://seekingalpha.com/symbol/DY' title='Dycom Industries Inc.'>DY</a>) <font color='red'>-12.1%</font> premarket after reporting better than expected <a href=\"https://seekingalpha.com/news/3292567-dycom-industries-beats-0_03-misses-revenue\" target=\"_blank\">FQ4 earnings</a>, as contract revenues fell to $780M from $789M a year ago and coming in below the analyst consensus of $799M.</li>     <li>DY issues downside guidance for FQ1, seeing EPS of $0.81-$0.96, far short of the $1.43 consensus estimate, on contract revenues of $715M-$745M, below the $785M consensus.</li>     <li>FBR Capital nevertheless reiterates its Buy recommendation, continuing to see DY as uniquely positioned to benefit from a massive upgrade to the wireline infrastructure in the U.S. over the next five-plus years and in the next wireless network upgrade cycle, which the firm expects to start in 2018 (source:&nbsp;Briefing.com).</li></ul><div class=\"tiny-share-widget\" data-id=\"3292664\" data-linked=\"Dycom -12% following revenue miss, weakened guidance\" data-tweet=\"$DY - Dycom -12% following revenue miss, weakened guidance https://seekingalpha.com/news/3292664-dycomminus-12-following-revenue-miss-weakened-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3292664-dycomminus-12-following-revenue-miss-weakened-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292655\" data-ts=\"1504098649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292655-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a>&nbsp;<font color='red'>-82%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16926941-otonomy-reports-results-avertsminus-1-phase-3-trial-otividex-patients-menieres-disease\" target=\"_blank\">reporting</a> results for AVERTS-1 Phase 3 trial for OTIVIDEX in patients with Meniere disease.</li><li><a href='https://seekingalpha.com/symbol/DY' title='Dycom Industries Inc.'>DY</a>&nbsp;<font color='red'>-14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292567-dycom-industries-beats-0_03-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292594-chicos-fas-misses-0_03-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292495-h-and-amp-r-block-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292655\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$OTIC $DY $CHS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3292655-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292655-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292648\" data-ts=\"1504098045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNED\" target=\"_blank\">BNED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292648-weak-textbook-sales-barnes-noble-education\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak textbook sales at Barnes &amp; Noble Education</a></h4><ul> <li>Barnes &amp; Noble Education (NYSE:<a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a>) heads lower in premarket trading after the company falls short of estimates with <a href=\"https://seekingalpha.com/pr/16927140-barnes-and-noble-education-reports-first-quarter-2018-financial-results\" target=\"_blank\">FQ1</a> revenue.</li> <li>College comparable store sales fell 2.5% during the quarter. Textbook sales were down 8.5%.</li> <li>Looking ahead, Barnes &amp; Noble Education sees consolidated sales falling in a range of $2.25B to $2.35B.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292635-barnes-and-noble-education-misses-revenue\" target=\"_blank\">Barnes &amp; Noble Education misses on revenue</a> (Aug. 30)</li> <li>BNED <font color='red'>-8.36%</font> premarket to $6.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292648\" data-linked=\"Weak textbook sales at Barnes &amp; Noble Education\" data-tweet=\"$BNED - Weak textbook sales at Barnes &amp; Noble Education https://seekingalpha.com/news/3292648-weak-textbook-sales-barnes-noble-education?source=tweet\" data-url=\"https://seekingalpha.com/news/3292648-weak-textbook-sales-barnes-noble-education\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292644\" data-ts=\"1504097323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292644-t2-biosystems-announces-11-new-patents-granted-in-2017-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T2 Biosystems announces 11 new patents granted in 2017; shares ahead 8% premarket</a></h4><ul><li>T2 Biosystems (NASDAQ:<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a>) <a href=\"https://seekingalpha.com/pr/16927076-t2-biosystems-announces-11-new-patents-granted-2017\" target=\"_blank\">announces</a> that it has been granted 11 new patents in 2017 that further broaden and strengthen the protection around the T2 Magnetic Resonance (T2MR) platform, including the T2Sepsis Solution and hemostasis technology. With the grant of these new patents, T2 Biosystems now owns or licenses over 60 patents.</li>   <li>Highlights of patents granted in 2017 are as follows:</li><li>Two patents cover the method and use of certain reagents for the company&rsquo;s primary diagnostic products that run on the T2Dx Instrument and support the T2Sepsis Solution.</li><li>Two patents cover the method and design of the automated sample lysis process.</li><li>One patent broadens the company&rsquo;s portfolio of T2MR detector patents for small, portable magnetic resonance detection devices.</li><li>One patent represents new intellectual property that covers an innovative method of integrating fluidics.</li><li>One patent covers probe sequences that can be used for high sensitivity detection of Candida species.</li><li>Four patents cover methods in the area of hemostasis.</li><li>The other patents in T2 Biosystems&rsquo; patent portfolio include patents with claims covering technical innovations.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3292644\" data-linked=\"T2 Biosystems announces 11 new patents granted in 2017; shares ahead 8% premarket\" data-tweet=\"$TTOO - T2 Biosystems announces 11 new patents granted in 2017; shares ahead 8% premarket https://seekingalpha.com/news/3292644-t2-biosystems-announces-11-new-patents-granted-in-2017-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292644-t2-biosystems-announces-11-new-patents-granted-in-2017-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292642\" data-ts=\"1504096848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADI\" target=\"_blank\">ADI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292642-analog-devices-up-4_1-after-q3-guidance-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analog Devices up 4.1% after Q3, guidance beats</a></h4><ul><li>        Analog Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices Inc.'>ADI</a>) shares are&nbsp;<font color='green'>up 4.1%</font>&nbsp;premarket after reporting Q3 results with EPS and revenue beats with revenue up over 64% on the year. Fourth quarter guidance has revenue from $1.45B to $1.55B, matching consensus on the lower end, and EPS from $1.29 to $1.43, above the $1.24 consensus. Gross margin expected at 70.5% and operating margin around 42%.</li><li>               End market revenue: Industrial, $700M (+87%); Automotive, $227.5M (+69%); Consumer, $252.5M (+36%); Communications, $253.7M (+45%).&nbsp;</li><li>               Key financials: Gross margin (non-GAAP) was 70.5%, up from 66% in last year&rsquo;s quarter and from 69.3% in Q2. Operating expenses were $437M and the company ended the quarter with $908.6M in cash and equivalents. &nbsp;&nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16927013-analog-devices-reports-third-quarter-2017-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292627-analog-devices-declares-0_45-dividend\" target=\"_blank\">Analog Devices declares $0.45 dividend</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292642\" data-linked=\"Analog Devices up 4.1% after Q3, guidance beats\" data-tweet=\"$ADI - Analog Devices up 4.1% after Q3, guidance beats https://seekingalpha.com/news/3292642-analog-devices-up-4_1-after-q3-guidance-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3292642-analog-devices-up-4_1-after-q3-guidance-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292641\" data-ts=\"1504096727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292641-vbi-vaccines-on-go-late-stage-study-of-sci-b-vac-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBI Vaccines on go with late-stage study of Sci-B-Vac; shares ahead 6% premarket</a></h4><ul><li>Thinly traded micro cap VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16927061-vbi-vaccines-announces-fda-acceptance-investigational-new-drug-application-sci-b-vac-r-phase\" target=\"_blank\">announcement </a>that the FDA has signed off on its IND for a Phase 3 program evaluating hepatitis B vaccine candidate Sci-B-Vac.</li><li>Health Canada is on board as well. A U.S./Canada clinical trial will commence later this year across ~40 sites.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292641\" data-linked=\"VBI Vaccines on go with late-stage study of Sci-B-Vac; shares ahead 6% premarket\" data-tweet=\"$VBIV - VBI Vaccines on go with late-stage study of Sci-B-Vac; shares ahead 6% premarket https://seekingalpha.com/news/3292641-vbi-vaccines-on-go-late-stage-study-of-sci-b-vac-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292641-vbi-vaccines-on-go-late-stage-study-of-sci-b-vac-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292640\" data-ts=\"1504096723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292640-sibanye-gold-swings-to-h1-loss-cancels-dividend-for-first-time\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sibanye Gold swings to H1 loss, cancels dividend for first time</a></h4><ul>     <li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a>) <font color='red'>-4%</font> premarket after canceling its dividend amid a $364M H1 loss</a>, citing impairments and <a href=\"http://www.reuters.com/article/us-sibanyegold-results-idUSKCN1BA0P9\" target=\"_blank\">provisions for an expected settlement</a> with miners who contracted lung diseases at work.</li>     <li>SBGL says it will <a href=\"https://www.bloomberg.com/news/articles/2017-08-30/sibanye-gold-halts-dividends-as-miner-focuses-on-lowering-debt\" target=\"_blank\">focus on cutting debt</a> after its $2.2B purchase of Stillwater Mining earlier this year, making the payment of a cash dividend &ldquo;inappropriate.&rdquo;</li>     <li>A class action lawsuit, mostly relating to the fatal lung disease silicosis, was filed on behalf of miners in 2012 and has led several companies to increase provisions related to the health and safety conditions.</li>     <li>The company also says it will change its name to Sibanye-Stillwater.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292640\" data-linked=\"Sibanye Gold swings to H1 loss, cancels dividend for first time\" data-tweet=\"$SBGL - Sibanye Gold swings to H1 loss, cancels dividend for first time https://seekingalpha.com/news/3292640-sibanye-gold-swings-to-h1-loss-cancels-dividend-for-first-time?source=tweet\" data-url=\"https://seekingalpha.com/news/3292640-sibanye-gold-swings-to-h1-loss-cancels-dividend-for-first-time\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292632\" data-ts=\"1504096293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRA\" target=\"_blank\">VRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292632-vera-bradley-breaks-higher-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley breaks higher after earnings</a></h4><ul> <li>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a>) reports comparable sales fell 4.3% in <a href=\"https://seekingalpha.com/pr/16927091-vera-bradley-announces-fiscal-second-quarter-2018-results\" target=\"_blank\">Q2</a> vs. -4.2% expected by analysts. E-commerce sales were down 4.9% during the quarter.</li> <li>Gross profit fell 110 bps to 56.3% of sales due in part to a higher level of promotional activity.</li> <li>\"We are in the process of refining our business model and strategic plan which will involve taking a much more aggressive approach to turning around our business over the next three years,\" says CEO Robert Wallstrom.</li> <li>The company expects Q3 revenue of $112M to $117M vs. $120M consensus and EPS of $0.13 to $0.15 vs. $0.16 consensus. Full-year EPS of $0.44 to $0.50 is seen vs. $0.44 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292613-vera-bradley-beats-0_03-beats-revenue\" target=\"_blank\">Vera Bradley beats by $0.03, beats on revenue</a> (Aug. 30)</li><li>VRA&nbsp;<font color='green'>+14.70%</font>&nbsp;premarket to $11.55.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292632\" data-linked=\"Vera Bradley breaks higher after earnings\" data-tweet=\"$VRA - Vera Bradley breaks higher after earnings https://seekingalpha.com/news/3292632-vera-bradley-breaks-higher-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3292632-vera-bradley-breaks-higher-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292622\" data-ts=\"1504095573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292622-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>La Jolla Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) initiated with Overweight and $36 price target by JPMorgan.</li><li>Reata Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a>) initiated with Buy rating and $44 price target by Jefferies. Shares up a fraction premarket.</li><li>Innate Pharma (<a href='https://seekingalpha.com/symbol/IPHYF' title='Innate Pharma'>OTCPK:IPHYF</a>) initiated with Buy rating and &euro;16.50 price target.</li><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) upgraded to Buy by Ladenburg Thalmann. Shares up&nbsp;<font color='green'>9%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292622\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$LJPC $LJPC $RETA - Premarket analyst action - healthcare https://seekingalpha.com/news/3292622-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3292622-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292618\" data-ts=\"1504095340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292618-post-earnings-dip-for-ollies-bargin-outlet-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings dip for Ollie&#39;s Bargin Outlet Stores</a></h4><ul> <li>Ollie's Bargain Outlet Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a>) reports comparable sales rose 4.5% in Q2 to mark an acceleration from the pace seen in Q1.</li> <li>Gross profit fell 30 bps to 39.4% of sales as merchandise margins tightened a bit. Operating income rose 130 bps to 11.7% of sales.</li> <li>Looking ahead, the retailer expects to report full year revenue of $1.045B to $1.052B vs. $1.04B consensus and EPS of $0.27 vs. $0.25 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292488-ollies-bargain-outlet-beats-0_02-beats-revenue\" target=\"_blank\">Ollie's Bargain Outlet beats by $0.02, beats on revenue</a> (Aug. 29)</li> <li>OLLI <font color='red'>-3.34%</font> premarket to $41.86.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292618\" data-linked=\"Post-earnings dip for Ollie&#39;s Bargin Outlet Stores\" data-tweet=\"$OLLI - Post-earnings dip for Ollie&#39;s Bargin Outlet Stores https://seekingalpha.com/news/3292618-post-earnings-dip-for-ollies-bargin-outlet-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3292618-post-earnings-dip-for-ollies-bargin-outlet-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292613\" data-ts=\"1504094617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRA\" target=\"_blank\">VRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292613-vera-bradley-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley beats by $0.03, beats on revenue</a></h4><ul><li>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a>): Q2 EPS of $0.13 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $112.4M (-5.7% Y/Y) <font color='green'>beats by $0.68M</font>.</li><li>Shares <font color='green'>+8.2%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16927091-vera-bradley-announces-fiscal-second-quarter-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292613\" data-linked=\"Vera Bradley beats by $0.03, beats on revenue\" data-tweet=\"$VRA - Vera Bradley beats by $0.03, beats on revenue https://seekingalpha.com/news/3292613-vera-bradley-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292613-vera-bradley-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292599\" data-ts=\"1504094614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292599-mazor-robotics-and-medtronic-enter-next-phase-of-strategic-partnership-shares-of-mazor-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mazor Robotics and Medtronic enter next phase of strategic partnership; shares of Mazor up 6% premarket</a></h4><ul> <li>Mazor Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a>) <a href=\"https://seekingalpha.com/pr/16926808-mazor-robotics-medtronic-enter-next-phase-strategic-partnership-medtronic-make-40-million\" target=\"_blank\">announces</a> that it has       entered the next phase of its strategic partnership with Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) earlier than planned.</li>          <li>Key highlights of the agreement are as follows:</li><li>Medtronic assumes exclusive global spine market commercial         responsibility for the Mazor X Surgical Assurance Platform and its         accessories.</li><li>The implementation of annual minimums for purchase of Mazor X systems         by Medtronic with a cumulative potential of hundreds of Mazor X         systems over a four and a half-year period.</li><li>Approximately 30 Mazor salespeople will join Medtronic to assure continuation of the current         momentum.</li><li>Medtronic will invest $40M in Mazor at $38.46 per ADS. This third tranche of investment will bring Medtronic&rsquo;s total investment in Mazor to         $72M, representing ~11.9% of the outstanding         shares post investment and 10.6% of the fully diluted shares.</li><li>Mazor will also issue to Medtronic         warrants to purchase an additional 1.21M Mazor ADSs at an         exercise price of $44.23 per ADS representing 15% premium. Medtronic has the right to exercise the warrants         immediately in whole or in part, for cash, and they expire after 18         months. Assuming the full exercise of the warrants, Medtronic&rsquo;s         investment in Mazor will reach $125M and its ownership could         increase to 4.2M ADSs, or 14.2%. Closing date of the $40M         equity investment is September 12.</li>                    <li>Mazor will continue to independently develop and market globally the       Renaissance Surgical Guidance System.</li>          <li>The Company will host a conference call at 8:30 AM ET.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on modest volume.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3292599\" data-linked=\"Mazor Robotics and Medtronic enter next phase of strategic partnership; shares of Mazor up 6% premarket\" data-tweet=\"$MDT $MZOR $MDT - Mazor Robotics and Medtronic enter next phase of strategic partnership; shares of Mazor up 6% premarket https://seekingalpha.com/news/3292599-mazor-robotics-and-medtronic-enter-next-phase-of-strategic-partnership-shares-of-mazor-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3292599-mazor-robotics-and-medtronic-enter-next-phase-of-strategic-partnership-shares-of-mazor-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292604\" data-ts=\"1504094136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292604-fda-oks-medicines-companys-vabomere-antibiotic-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs The Medicines Company&#39;s Vabomere antibiotic; shares ahead 6% premarket</a></h4><ul><li>The Medicines Company (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) is up<font color='green'> 6%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16926915-medicines-company-announces-fda-approval-vabomere-meropenem-vaborbactam\" target=\"_blank\">announcement</a> that the FDA has approved VABOMERE (meropenem and vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis.</li><li>VABOMERE had Priority Review and Qualified Infectious Disease Product status, the latter of which provides for an additional five-year period of market exclusivity. The company expects its patent coverage and QIDP status to provide exclusivity in the U.S. into 2031.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292604\" data-linked=\"FDA OKs The Medicines Company&#39;s Vabomere antibiotic; shares ahead 6% premarket\" data-tweet=\"$MDCO - FDA OKs The Medicines Company&#39;s Vabomere antibiotic; shares ahead 6% premarket https://seekingalpha.com/news/3292604-fda-oks-medicines-companys-vabomere-antibiotic-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292604-fda-oks-medicines-companys-vabomere-antibiotic-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292600\" data-ts=\"1504093930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHS\" target=\"_blank\">CHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292600-chicos-plunges-after-sales-and-margins-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chico&#39;s plunges after sales and margins disappoint</a></h4><ul> <li>Chico's FAS (NYSE:<a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a>) reports comparable sales fell 8.4% in <a href=\"https://seekingalpha.com/pr/16926961-chicos-fas-inc-reports-second-quarter-results\" target=\"_blank\">Q2</a> as negative comps were recorded for the White House Black Market, Chico's and Soma brands.</li> <li>Gross margin came in at 36.1% of sales vs. 37.9% a year ago and 37.4% consensus. SG&amp;A expenses rose 60 bps to 30.0% of sales.</li> <li>\"Second quarter sales were disappointing, and we are taking decisive actions to adjust our assortments and enhance omni-channel capabilities in bellwether categories such as Jackets at Chico's and Dresses at White House Black Market,\" says CEO Shelley Broader.</li> <li>Looking ahead, Chico's expects comparable sales to be down high single-digits in FY17 with gross margin rate decreasing by approximately 75 to 100 basis points.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292594-chicos-fas-misses-0_03-misses-revenue\" target=\"_blank\">Chico's FAS misses by $0.03, misses on revenue</a> (Aug. 30)</li> <li>CHS <font color='red'>-12.90%</font> premarket to $6.82.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292600\" data-linked=\"Chico&#39;s plunges after sales and margins disappoint\" data-tweet=\"$CHS - Chico&#39;s plunges after sales and margins disappoint https://seekingalpha.com/news/3292600-chicos-plunges-after-sales-and-margins-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3292600-chicos-plunges-after-sales-and-margins-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292598\" data-ts=\"1504093204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292598-lilly-to-refile-u-s-marketing-application-for-ra-med-baricitinib-in-january-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly to refile U.S. marketing application for RA med baricitinib in January 2018</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) gives shareholders some good news this morning with its <a href=\"https://seekingalpha.com/pr/16926903-lilly-file-baricitinib-resubmission-u-s-fda-end-january-2018\" target=\"_blank\">announcement </a>that, after discussions with the FDA, it plans to resubmit its New Drug Application &#40;NDA&#41; for rheumatoid arthritis &#40;RA&#41; med baricitinib by the end of January 2018. The refiling will include new safety and efficacy data.</li><li>The company received a CRL in April citing the need for additional clinical data to support the optimum doses and additional data to further characterize the safety profile across treatment arms.</li><li>In July, the company said it did not anticipate refiling for at least 18 months. It also believes the FDA will regard it as a Class II resubmission which has a six-month review cycle.</li><li>Lilly co-developed baricitinib, an oral JAK inhibitor, with Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>), under a December 2009 agreement. It was approved in Europe in February and Japan in July.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257187-fda-rejects-lillys-marketing-application-ra-candidate-baricitinib\" target=\"_blank\">FDA rejects Lilly's marketing application for RA candidate baricitinib</a> (April 14)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280851-refiling-u-s-marketing-application-arthritis-med-baricitinib-least-18-months-away-lilly-1\" target=\"_blank\">Refiling of U.S. marketing application for arthritis med baricitinib at least 18 months away, Lilly down 1%, Incyte down 4% premarket</a> (July 25)</li><li><strong>Update</strong>: LLY is up&nbsp;<font color='green'>3%</font>&nbsp;and INCY&nbsp;<font color='green'>8%</font>&nbsp;mid-session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292598\" data-linked=\"Lilly to refile U.S. marketing application for RA med baricitinib in January 2018\" data-tweet=\"$LLY $LLY $INCY - Lilly to refile U.S. marketing application for RA med baricitinib in January 2018 https://seekingalpha.com/news/3292598-lilly-to-refile-u-s-marketing-application-for-ra-med-baricitinib-in-january-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3292598-lilly-to-refile-u-s-marketing-application-for-ra-med-baricitinib-in-january-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292591\" data-ts=\"1504092188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTIC\" target=\"_blank\">OTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292591-otonomys-otividex-flunks-late-stage-study-in-meniere-s-disease\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Otonomy&#39;s Otividex flunks late-stage study in Ménière\u2019s disease</a></h4><ul><li>A Phase 3 clinical trial, AVERTS-1, assessing Otonomy's (NASDAQ:<a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a>) OTIVIDEX in patients with an inner ear disorder called M&eacute;ni&egrave;re&rsquo;s disease <a href=\"https://seekingalpha.com/pr/16926941-otonomy-reports-results-avertsminus-1-phase-3-trial-otividex-patients-menieres-disease\" target=\"_blank\">failed to achieve</a> its primary endpoint of a statistically valid reduction in the number of vertigo days from baseline compared to placebo (58% vs. 55%; p=0.62). The study also failed to achieve any of the key secondary vertigo endpoints.</li><li>CEO David Weber, Ph.D., says, &ldquo;We are greatly disappointed by these results, and surprised by both the higher placebo response and lower OTIVIDEX improvement than observed in our previous trials. I would like to thank the many patients and investigators who participated in our M&eacute;ni&egrave;re&rsquo;s clinical program. Based on these results, we are immediately suspending all development activities for OTIVIDEX including the ongoing AVERTS-2 trial. In addition, the company is undertaking a review of its product pipeline and commercial efforts to identify opportunities to extend its cash runway and build shareholder value.\"</li><li>OTIVIDEX (formerly&nbsp;<a href=\"http://www.otonomy.com/pipeline/oto-104/\" target=\"_blank\">OTO-104</a>),&nbsp;a sustained-exposure formulation of the steroid dexamethasone, was being developed to treat a range of balance and hearing disorders. It is administered directly into the middle ear via injection through the eardrum.</li><li>The company is withdrawing its previously announced spending guidance for 2017 of $80M - 85M. As of June 30, its cash balance was $150.5M.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li><li>Nasdaq has not listed the premarket trading activity yet, but shareholders should expect a significant down move.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>71%</font>&nbsp;in initial trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292591\" data-linked=\"Otonomy&#39;s Otividex flunks late-stage study in Ménière\u2019s disease\" data-tweet=\"$OTIC - Otonomy&#39;s Otividex flunks late-stage study in Ménière\u2019s disease https://seekingalpha.com/news/3292591-otonomys-otividex-flunks-late-stage-study-in-meniere-s-disease?source=tweet\" data-url=\"https://seekingalpha.com/news/3292591-otonomys-otividex-flunks-late-stage-study-in-meniere-s-disease\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292589\" data-ts=\"1504091316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COTY\" target=\"_blank\">COTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292589-berenberg-loses-confidence-in-coty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Berenberg loses confidence in Coty</a></h4><ul> <li>Berenberg Bank lowers Coty (NYSE:<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a>) to a <a href=\"https://www.streetinsider.com/Analyst+Comments/Berenberg+Downgrades+Coty+Inc.+%28COTY%29+to+Sell/13250061.html\" target=\"_blank\">Sell rating</a> after having the cosmetics stock set at Hold.</li> <li>Reduced visibility on Coty's path to improved margins is cited as a reason for the ratings action.</li> <li>The German investment firm drops its price target to $15 from $17.50.</li><li>COTY&nbsp;<font color='red'>-0.91%</font>&nbsp;premarket to $16.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292589\" data-linked=\"Berenberg loses confidence in Coty\" data-tweet=\"$COTY - Berenberg loses confidence in Coty https://seekingalpha.com/news/3292589-berenberg-loses-confidence-in-coty?source=tweet\" data-url=\"https://seekingalpha.com/news/3292589-berenberg-loses-confidence-in-coty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292581\" data-ts=\"1504090787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTIC\" target=\"_blank\">OTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292581-otonomy-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Otonomy trading halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Otonomy (NASDAQ:<a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a>) pending the release of news.</li><li>The release of top-line results from a clinical trial assessing Otividex in Meniere's disease is the next key event.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292581\" data-linked=\"Otonomy trading halted pending news\" data-tweet=\"$OTIC - Otonomy trading halted pending news https://seekingalpha.com/news/3292581-otonomy-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3292581-otonomy-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM </div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}